These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15544487)

  • 21. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of ovulation: comparison between the mechanism of action of steroids and GnRH analogues.
    Bouchard P; Wolf JP; Hajri S
    Hum Reprod; 1988 May; 3(4):503-6. PubMed ID: 3292571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?
    Tolkach Y; Joniau S; Van Poppel H
    BJU Int; 2013 Jun; 111(7):1021-30. PubMed ID: 23418666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leuprolide acetate: a drug of diverse clinical applications.
    Wilson AC; Meethal SV; Bowen RL; Atwood CS
    Expert Opin Investig Drugs; 2007 Nov; 16(11):1851-63. PubMed ID: 17970643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics.
    Hayes FJ; Taylor AE; Martin KA; Hall JE
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2343-9. PubMed ID: 9661606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Luteinising hormone-releasing hormone antagonists in prostate cancer therapy.
    Msaouel P; Diamanti E; Tzanela M; Koutsilieris M
    Expert Opin Emerg Drugs; 2007 May; 12(2):285-99. PubMed ID: 17604502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical consequences of the administration of a GnRH antagonist during the menstrual cycle].
    Gordon K
    J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S7-10. PubMed ID: 15643677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence that GnRH decreases with gonadal steroid feedback but increases with age in postmenopausal women.
    Gill S; Sharpless JL; Rado K; Hall JE
    J Clin Endocrinol Metab; 2002 May; 87(5):2290-6. PubMed ID: 11994378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists.
    Tan O; Bukulmez O
    Curr Opin Obstet Gynecol; 2011 Aug; 23(4):238-44. PubMed ID: 21666463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel peptides in ovarian follicular fluid: implications for contraceptive development.
    Schwartz NB
    Res Front Fertil Regul; 1982 Sep; 2(2):1-11. PubMed ID: 12179632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.
    Yen SS
    Fertil Steril; 1983 Mar; 39(3):257-66. PubMed ID: 6130985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pituitary and extrapituitary actions of gonadotrophin-releasing hormone and its analogues.
    Ortmann O; Diedrich K
    Hum Reprod; 1999 Sep; 14 Suppl 1():194-206. PubMed ID: 10573034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A clinician's guide to the use of gonadotropin-releasing hormone analogues in women.
    Moghissi KS
    Medscape Womens Health; 2000 Jan; 5(1):5. PubMed ID: 10792849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role, mechanism of action and application of gonadoliberins in reproductive processes.
    Teplán I
    Acta Biol Hung; 1989; 40(1-2):3-36. PubMed ID: 2561244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kisspeptin antagonists.
    Roseweir AK; Millar RP
    Adv Exp Med Biol; 2013; 784():159-86. PubMed ID: 23550006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing subcutaneous injection of the gonadotropin-releasing hormone receptor antagonist degarelix.
    Barkin J; Burton S; Lambert C
    Can J Urol; 2016 Feb; 23(1):8179-83. PubMed ID: 26892063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902.
    Struthers RS; Xie Q; Sullivan SK; Reinhart GJ; Kohout TA; Zhu YF; Chen C; Liu XJ; Ling N; Yang W; Maki RA; Bonneville AK; Chen TK; Bozigian HP
    Endocrinology; 2007 Feb; 148(2):857-67. PubMed ID: 17095587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer.
    Liu YF; Fu SQ; Yan YC; Gong BB; Xie WJ; Yang XR; Sun T; Ma M
    Drug Des Devel Ther; 2021; 15():639-649. PubMed ID: 33623372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamprey GnRH-III acts on its putative receptor via nitric oxide to release follicle-stimulating hormone specifically.
    Yu WH; Karanth S; Mastronardi CA; Sealfon S; Dean C; Dees WL; McCann SM
    Exp Biol Med (Maywood); 2002 Oct; 227(9):786-93. PubMed ID: 12324658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.